Suven Life Sciences Limited has informed the Exchange regarding Board meeting held on July 16, 2025. Allotment of 91,86,490 Equity Shares of the Company on preferential basis upon conversion 91,86,490 fully paid warrants
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.3 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Suven Life Sciences, at its meeting on July 16, 2025, approved the conversion of 91,86,490 fully paid warrants into equity shares at Rs. 134 per share on a preferential basis. The total consideration received from this conversion is Rs. 123.10 crore, which has been fully paid by the allottees. The shares were allotted to three non-promoter entities: Quant Mutual Fund (47,01,490 shares), Abakkus Diversified Alpha Fund (29,85,000 shares), and Cobra India (Mauritius) Limited (15,00,000 shares). Following this allotment, the company's paid-up equity share capital has increased from Rs. 21.81 crore (21,80,73,717 shares) to Rs. 22.73 crore (22,72,60,207 shares), resulting in approximately 4.2% equity dilution for existing shareholders.
Existing shareholders will face about 4.2% equity dilution due to the new share issuance. However, the participation of marquee institutional investors like Quant Mutual Fund signals confidence in the company's prospects, and the company has received the full Rs. 123.10 crore in cash, strengthening its balance sheet for future growth.